Literature DB >> 22843295

Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

V Waters1, J E A Zlosnik, Y C W Yau, D P Speert, S D Aaron, D S Guttman.   

Abstract

The aim of this study was to compare two traditional pattern matching techniques, pulsed-field gel electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD), with the more reproducible technique of multilocus sequence typing (MLST) to genotype a blinded sample of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients. A blinded sample of 48 well-characterized CF P. aeruginosa isolates was genotyped by PFGE, RAPD, and MLST, each performed in a different laboratory. The discriminatory power and congruence between the methods were compared using the Simpson's index, Rand index, and Wallace coefficient. PFGE and MLST had the greatest congruence with the highest Rand index (0.697). The discriminatory power of PFGE, RAPD, and MLST were comparable, with high Simpson's indices (range 0.973-0.980). MLST identified the most clonal relationships. When clonality was defined as agreement between two or more methods, MLST had the greatest predictive value (100 %) in labeling strains as unique, while PFGE had the greatest predictive value (96 %) in labeling strains as clonal. This study demonstrated the highest level of agreement between PFGE and MLST in genotyping P. aeruginosa isolates from CF patients. MLST had the greatest predictive value in identifying strains as unique and, thus, has the potential to be a cost-efficient, high-throughput, first-pass typing method.

Entities:  

Mesh:

Year:  2012        PMID: 22843295     DOI: 10.1007/s10096-012-1701-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms.

Authors:  H Grundmann; S Hori; G Tanner
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Diagnostic multiplex PCR assay for the identification of the Liverpool, Midlands 1 and Manchester CF epidemic strains of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Anna L Upton; Tyrone L Pitt; C Anthony Hart; Craig Winstanley
Journal:  J Cyst Fibros       Date:  2007-10-29       Impact factor: 5.482

3.  An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

Authors:  S S Pedersen; C Koch; N Høiby; K Rosendal
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

Review 5.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

6.  Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.

Authors:  Richard Bradbury; Alan Champion; David W Reid
Journal:  Respirology       Date:  2008-11       Impact factor: 6.424

7.  Cross-sectional and longitudinal multilocus sequence typing of pseudomonas aeruginosa in cystic fibrosis sputum samples.

Authors:  David J Waine; David Honeybourne; E Grace Smith; Joanna L Whitehouse; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

8.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

Review 9.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Am J Infect Control       Date:  2003-05       Impact factor: 2.918

10.  Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics.

Authors:  J Schmid; L J Ling; J L S Leung; N Zhang; J Kolbe; A W Wesley; G D Mills; P J Brown; D T Jones; R T R Laing; P K Pattemore; D R Taylor; K Grimwood
Journal:  Eur Respir J       Date:  2008-08-20       Impact factor: 16.671

View more
  17 in total

1.  Genotypic diversity of Pseudomonas aeruginosa in cystic fibrosis siblings in Qatar using AFLP fingerprinting.

Authors:  A Abdul Wahab; S J Taj-Aldeen; F Hagen; S Diophode; A Saadoon; J F Meis; C H Klaassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-01       Impact factor: 3.267

2.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 3.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

4.  Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Authors:  M Workentine; A Poonja; B Waddell; J Duong; D G Storey; D Gregson; R Somayaji; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

5.  SNaPBcen: a novel and practical tool for genotyping Burkholderia cenocepacia.

Authors:  Nadia Eusebio; Carla P Coutinho; Isabel Sá-Correia; Ricardo Araujo
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

6.  Population structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Authors:  Ana Fernández-Olmos; María García-Castillo; José María Alba; María Isabel Morosini; Adelaida Lamas; Beatriz Romero; Juan Carlos Galán; Rosa del Campo; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

7.  Antibiotic Resistance Patterns and Genetic Diversity in Clinical Isolates of Pseudomonas aeruginosa Isolated From Patients of a Referral Hospital, Isfahan, Iran.

Authors:  Hamid Vaez; Jamshid Faghri; Bahram Nasr Esfahani; Sharareh Moghim; Hossein Fazeli; Mansour Sedighi; Hajieh Ghasemian Safaei
Journal:  Jundishapur J Microbiol       Date:  2015-08-01       Impact factor: 0.747

8.  Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients.

Authors:  Atqah AbdulWahab; Saad J Taj-Aldeen; Emad Ibrahim; Shaikha H Abdulla; Ramees Muhammed; Irshad Ahmed; Yasmine Abdeen; Omnia Sadek; Marawan Abu-Madi
Journal:  Infect Drug Resist       Date:  2014-11-20       Impact factor: 4.003

9.  Genotypic and phenotypic relatedness of Pseudomonas aeruginosa isolates among the major cystic fibrosis patient cohort in Italy.

Authors:  Cristina Cigana; Paola Melotti; Rossella Baldan; Elisa Pedretti; Emily Pintani; Patrizia Iansa; Ida De Fino; Flavio Favari; Gabriella Bergamini; Gloria Tridello; Daniela M Cirillo; Baroukh M Assael; Alessandra Bragonzi
Journal:  BMC Microbiol       Date:  2016-07-11       Impact factor: 3.605

10.  SNaPaer: a practical single nucleotide polymorphism multiplex assay for genotyping of Pseudomonas aeruginosa.

Authors:  Nadia Eusebio; Tiago Pinheiro; Adelina A Amorim; Fernanda Gamboa; Lucília Saraiva; Leonor Gusmão; António Amorim; Ricardo Araujo
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.